부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.vetimm.2006.01.008 Byline: J.M. Minke (a), L. Fischer (a), Ph. Baudu (a), P.M. Guigal (a), T. Sindle (b), J.A. Mumford (b), J.C. Audonnet (a) Keywords: EHV-1; Vaccination; Canarypox vector; DNA vaccination Abbreviations: CF, complement fixing antibody; DNA, deoxyribonucleic acid; EHV, equine herpes virus; TCID, tissue culture infectious dose; VN, virus neutralising antibody; MHC, major histocompatibility complex Abstract: In this study, experimental canarypox virus (ALVAC) and plasmid DNA recombinant vaccines expressing the gB, gC and gD glycoproteins of EHV-1 were assessed for their ability to protect conventional ponies against a respiratory challenge with EHV-1. In addition, potential means of enhancing serological responses in horses to ALVAC and DNA vaccination were explored. These included co-administration of the antigen with conventional adjuvants, complexation with DMRIE-DOPE and co-expression of the antigen along with equine GM-CSF. Groups of EHV primed ponies were vaccinated twice intra-muscularly with one dose of the appropriate test vaccine at an interval of 5 weeks. Two to 3 weeks after the second vaccination, ponies were infected intra-nasally with the virulent Ab4 strain of EHV-1 after which they were observed clinically and sampled for virological investigations. The results demonstrated that DNA and ALVAC vaccination markedly reduced virus excretion after challenge in terms of duration and magnitude, but failed to protect against cell-associated viremia. Noteworthy was the almost complete absence of virus excretion in the group of ponies vaccinated with ALVAC-EHV in the presence of Carbopol adjuvant or DNA plasmid formulated with aluminium phosphate. The administration of the DNA vaccine in the presence of GM-CSF and formulated in DMRIE-DOPE and of the ALVAC vaccine in the presence of Carbopol adjuvant significantly improved virus neutralising antibody responses to EHV-1. These findings indicate that DNA and ALVAC vaccination is a promising approach for the immunological control of EHV-1 infection, but that more research is needed to identify the immunodominant protective antigens of EHV-1 and their interaction with the equine immune system. Author Affiliation: (a) Merial SAS, 254 rue Marcel Merieux, 69007 Lyon, France (b) Centre for Preventive Medicine, Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk CB8 7UU, UK